MKP1 repression is required for the chemosensitizing effects of NF-κB and PI3K inhibitors to cisplatin in non-small cell lung cancer

Cancer Letters

Volumn 286, Issue 2, 2009, Pages 206-216

  Cortes Sempere, María ^a,b   Chattopadhyay, Sharmila ^e   Rovira, Ana ^d   Rodriguez Fanjul, Vanessa ^a,b   Belda Iniesta, Cristobal ^c   Tapia, Marian ^d   Cejas, Paloma ^c   Machado Pinilla, Rosario ^a,b   Manguan García, Cristina ^a,b   Sánchez Pérez, Isabel ^a,b   Nistal, Manuel ^c   Moratilla, Carmen ^a   Castro Carpeño, Javier de ^c   Gonzalez Barón, Manuel ^c   Albanell, Joan ^d   Perona, Rosario ^a,b  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d HOSPITAL DEL MAR   (Spain)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bortezomib; Cisplatin; Jun kinase; MKP1 DUSP1 siRNA; NF B relB; Non small cell lung cancer; PI3K Akt; Proteasome

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; BORTEZOMIB; CISPLATIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEASOME; PROTEIN KINASE B; SMALL INTERFERING RNA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CHEMOSENSITIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REPRESSION; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BORONIC ACIDS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; CHROMONES; CISPLATIN; DUAL SPECIFICITY PHOSPHATASE 1; HUMANS; IMMUNOHISTOCHEMISTRY; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LUNG NEOPLASMS; MORPHOLINES; NF-KAPPA B; NITRILES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZINES; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SULFONES;

EID: 71549164074     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.05.029     Document Type: Article

References (40)

1. Eastman A. Interstrand cross-links and sequence specificity in the reaction of cis-dichloro(ethylenediamine)platinum(II) with DNA. Biochemistry 24 (1985) 27-32
2. Sanchez-Perez I., Martinez-Gomariz M., Williams D., Keyse S.M., and Perona R. CL100/MKP-1 modulates JNK activation and apoptosis in response to cisplatin. Oncogene 19 (2000) 5142-5152
3. Sanchez-Perez I., Murguia J.R., and Perona R. Cisplatin induces a persistent activation of JNK that is related to cell death. Oncogene 16 (1998) 533-540
4. Sanchez-Perez I., and Perona R. Lack of c-Jun activity increases survival to cisplatin. FEBS Lett. 453 (1999) 151-158
5. Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2 (2002) 489-501
6. Baldwin A.S. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J. Clin. Invest. 107 (2001) 241-246
7. Lau L.F., and Nathans D. Identification of a set of genes expressed during the G0/G1 transition of cultured mouse cells. EMBO J. 4 (1985) 3145-3151
8. Charles C.H., Abler A.S., and Lau L.F. cDNA sequence of a growth factor-inducible immediate early gene and characterization of its encoded protein. Oncogene 7 (1992) 187-190
9. Chattopadhyay S., Machado-Pinilla R., Manguan-Garcia C., et al. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer. Oncogene 25 (2006) 3335-3345
10. Toker A., and Newton A.C. Cellular signaling: pivoting around PDK-1. Cell 103 (2000) 185-188
11. Wymann M.P., and Pirola L. Structure and function of phosphoinositide 3-kinases. Biochim. Biophys. Acta 1436 (1998) 127-150
12. Di Cristofano A., and Pandolfi P.P. The multiple roles of PTEN in tumor suppression. Cell 100 (2000) 387-390
13. Datta S.R., Dudek H., Tao X., et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91 (1997) 231-241
14. Cardone M.H., Roy N., Stennicke H.R., et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 282 (1998) 1318-1321
15. Chun K.H., Kosmeder II J.W., Sun S., et al. Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J. Natl. Cancer Inst. 95 (2003) 291-302
16. 2-terminal kinase-dependent pathways cooperate to maintain lung cancer cell survival. J. Biol. Chem. 278 (2003) 23630-23638
17. Brognard J., Clark A.S., Ni Y., and Dennis P.A. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 61 (2001) 3986-3997
18. 2-terminal kinase pathways: an effective therapeutic strategy for lung cancer. Clin. Cancer Res. 11 (2005) 6065-60674
19. Wang C.Y., Guttridge D.C., Mayo M.W., and Baldwin Jr. A.S. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol. Cell. Biol. 19 (1999) 5923-5929
20. Finco T.S., and Baldwin A.S. Mechanistic aspects of NF-kappa B regulation: the emerging role of phosphorylation and proteolysis. Immunity 3 (1995) 263-272
21. Matthews J.R., and Hay R.T. Regulation of the DNA binding activity of NF-kappa B. Int. J. Biochem. Cell Biol. 27 (1995) 865-879
22. Bonizzi G., and Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 25 (2004) 280-288
23. Brown K., Gerstberger S., Carlson L., Franzoso G., and Siebenlist U. Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation. Science 267 (1995) 1485-1488
24. Traenckner E.B., Pahl H.L., Henkel T., Schmidt K.N., Wilk S., and Baeuerle P.A. Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli. EMBO J. 14 (1995) 2876-28783
25. DiDonato J., Mercurio F., Rosette C., et al. Mapping of the inducible IkappaB phosphorylation sites that signal its ubiquitination and degradation. Mol. Cell. Biol. 16 (1996) 1295-1304
26. Dejardin E., Droin N.M., Delhase M., et al. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 17 (2002) 525-535
27. Sanchez-Perez I., Benitah S.A., Martinez-Gomariz M., Lacal J.C., and Perona R. Cell stress and MEKK1-mediated c-Jun activation modulate NF-κB activity and cell viability. Mol. Biol. Cell 13 (2002) 2933-2945
28. Devary Y., Rosette C., DiDonato J.A., and Karin M. NF-kappa B activation by ultraviolet light not dependent on a nuclear signal. Science 261 (1993) 1442-1445
29. Russo A., Fratto M.E., Bazan V., Schiró V., Agnese V., Cicero G., Vincenzi B., Tonini G., and Santini D. Targeting apoptosis in solid tumors: the role of Bortezomib from preclinical to clinical evidence. Expert. Opin. Ther. Targets 11 (2007) 1571-1586
30. Perona R., Montaner S., Saniger L., Sanchez-Perez I., Bravo R., and Lacal J.C. Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins. Genes Dev. 11 (1997) 463-475
31. Schmitz M.L., dos Santos Silva M.A., and Baeuerle P.A. Transactivation domain 2 (TA2) of p65 NF-kappa B. Similarity to TA1 and phorbol ester-stimulated activity and phosphorylation in intact cells. J. Biol. Chem. 270 (1995) 15576-15584
32. Tichelaar J.W., Zhang Y., leRiche J.C., Biddinger P.W., Lam S., and Anderson M.W. Increased staining for phospho-Akt, p65/RELA and cIAP-2 in pre-neoplastic human bronchial biopsies. BMC Cancer 5 (2005) 155-159
33. Tsurutani J., Steinberg S.M., Ballas M., et al. Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma. Lung Cancer 55 (2007) 115-121
34. Tsurutani J., Castillo S.S., Brognard J., et al. Tobacco components stimulate Akt-dependent proliferation and NFkappaB-dependent survival in lung cancer cells. Carcinogenesis 26 (2005) 1182-1195
35. Mabuchi S., Ohmichi M., Nishio Y., et al. Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J. Biol. Chem. 279 (2004) 23477-23485
36. Dejardin E. The alternative NF-kappaB pathway from biochemistry to biology: pitfalls and promises for future drug development. Biochem. Pharmacol. 72 (2006) 1161-1179
37. Voboril R., Hochwald S.N., Li J., et al. Inhibition of NF-kappa B augments sensitivity to 5-fluorouracil/folinic acid in colon cancer. J. Surg. Res. 120 (2004) 178-188
38. Montagut C., Tusquets I., Ferrer B., et al. Activation of nuclear factor-kappa B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients. Endocr. Relat. Cancer 13 (2006) 607-616
39. Wang X., Ju W., Renouard J., Aden J., Belinsky S.A., and Lin Y. 17-allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-kappaB pathway. Cancer Res. 66 (2006) 1089-1095
40. Fanucchi M.P., Fossella F.V., Belt R., Natale R., Fidias P., Carbone D.P., Govindan R., Raez L.E., Robert F., Ribeiro M., Akerley W., Kelly K., Limentani S.A., Crawford J., Reimers H.J., Axelrod R., Kashala O., Sheng S., and Schiller J.H. Randomized phase II study of Bortezomib alone and Bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J. Clin. Oncol. 24 (2006) 5025-5033